Rheumatoid arthritis (RA), a debilitating, chronic disease affects more than 1.5 million people in the United States alone and more than 2 million in Europe. Although there is no known cure for RA, multiple therapies are available today. Rheumatoid arthritis can make even the simplest tasks difficult. Advanced and developing technologies are helping patients with rheumatoid arthritis in simply day-to-day activities. To make these everyday tasks pain-free, strong-willed companies are driving this technology even further to help RA patients.
With a mission to provide rheumatologists with a deeper sense of clinical insights, Crescendo Bioscience helps to enable more effective management of patients with autoimmune and inflammatory diseases. “Our goal is to create a broad portfolio of specialty diagnostic tests that will enable more effective patient management and improve patient outcomes,” says the President of Crescendo Bioscience, Bernard Tobin.
Crescendo Bioscience is a wholly owned subsidiary of Myriad Genetics, Inc. Today, the company is a fast-growing organization offering a dynamic and exciting work environment. Based in South San Francisco, CA, it is primarily focused on serving the rheumatology community.
The Crescendo Offering
Crescendo Bioscience is creating comprehensive models of disease biology. With its deep expertise in genetics, gene expression, and quantitative protein analysis, the company is also establishing long-term, collaborative relationships with physicians. It also provides comprehensive diagnostic, prognostic, analysis, therapy selection, and monitoring capabilities to improve outcomes over the lifetime of each patient.
Moreover, Crescendo Bioscience also emphasizes and dedicates its efforts in rheumatology. When it comes to rheumatoid arthritis, each therapy is unique at different levels of effectiveness and significant potential toxicities. Often times, it is a back-breaking challenge to choose the optimal and right treatment from among these available therapeutic alternatives.
This is why; the company is putting in all its efforts and working with physicians, clinical researchers, healthcare administrators, and others to develop an overall strategy. Currently, Crescendo Bioscience offers:
Solutions that make a Difference
Crescendo Bioscience is developing a prospective outcomes study. Its prized solution, the Vectra DA guided care for RA patients with inadequate response to methotrexate. Vectra DA is an advanced blood test that helps healthcare providers and patients to better understand rheumatoid arthritis (RA) disease activity with a single score. Vectra DA blood test for RA gives a complete look at disease activity by measuring 12 markers of RA disease activity.
By working with collaborators in the leading academic medical institutions, Crescendo Bioscience is building a comprehensive understanding of the biology underlying autoimmune and inflammatory diseases, including the characterization of protein, gene expression, and genetic biomarkers.
Crescendo Bioscience is advancing its pipeline by leveraging its multi-biomarker platform to develop new tests. “We are focused on assay development that aids in the diagnosis of multiple inflammatory diseases, including psoriatic arthritis (PsA),” explains Tobin. The company has set its goal to develop a broad portfolio of specialty diagnostic tests that will enable more effective patient management and improve patient outcomes.
Empowering the People
“Each of us at Crescendo Bioscience is excited by being at the forefront of the precision medicine revolution,” says Tobin. Crescendo Bioscience especially highlights its focus in the fields of autoimmune and inflammatory disease. In one of its ongoing efforts, the company is bringing knowledge-based empowerment to patients, cost management solutions to payers, and objective decision-making tools to healthcare providers.
“Today, we are working on expanding the utility of Vectra DA to become the ultimate objective tool to support treatment decisions for patients with Rheumatoid Arthritis,” he explains. The primary goal of Crescendo Bioscience is to make a meaningful difference in patient lives. It also aims to make smart decisions on healthcare costs and help physicians make the best treatment decisions.
When it comes to its people, Crescendo Bioscience offers industry-competitive compensation and benefits. Top that with one of the best perks and work experience, the employees love it here! “Crescendo Bioscience is proud of its diverse and flexible work environment and we strive to empower our team members with the leadership, resources, and tools needed to succeed,” Tobin notes.
Here’s what others have to say about Crescendo Bioscience’s Vectra DA:
“The initial Vectra DA is the most critical, because…you’re going to be looking for the change in the Vectra DA score as you manage your patient’s rheumatoid arthritis.” –Dr. Andrew Sulich
“When we look at Vectra DA we are looking at a composite score…and that certainly has been more indicative of low disease activity or remission in our patients.” –Dr. Howard Busch
Meet the Pioneer
Bernard Tobin is the President of Crescendo Bioscience. He previously held several senior positions at Amgen, including Executive Director of National Accounts, General Manager of both the Netherlands and Brazil and Global Head of Commercial Excellence. In addition, he led the global integration of a business development acquisition in more than 100 countries. Prior to that, Mr. Tobin held a variety of leadership roles in the commercial organization at Eli Lilly and Co. He received his B.S. degree in public service and administration from Iowa State University and his M.B.A. from the Fuqua School of Business, Duke University.
“Our goal is to create a broad portfolio of specialty diagnostic tests that will enable more effective patient management and improve patient outcomes.”
“Each of us at Crescendo Bioscience is excited by being at the forefront of the precision medicine revolution.”
IBM Tops 2020 U.S. Patent List; IBM India 2nd Highest Contributor
SAP Invests €55M to Accelerate Its Cloud Strategy in India
LG Now Has a Controlling Stake In Alphonso
B2B E-Commerce Startup Udaan Raises $280 Million
Digital Healthcare Tech Company DXY Raises $500M
© 2021 CIO Bulletin. All rights reserved.